glp 1 fda compounding Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the Adverse Event Reporting System FDA Targets GLP-1 and Peptide

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect

On December 14, 2023, "Science" magazine announced the top ten scientific breakthroughs of the year

Sarcopenia is an age-related syndrome characterized by a progressive and extensive decline in skeletal muscle mass and function, leading to serious impairment of the quality of life and poor health prognosis in older adults

New findings highlight the effectiveness of GLP-1 receptor agonists like tirzepatide, semaglutide, and retatrutide for weight loss in adults without diabetes

GLP-1 Up by Ora Organic: four patented plant extracts clinically studied to support natural GLP-1 production, blood sugar balance, metabolic health, and satiety

Semaglutide and other GLP-1 medications may influence cortisol regulation during weight loss, though direct cortisol suppression is not their primary mechanism